Evotec SE
TIAP and Evotec Expand LAB150 Bridge Partnership to Include Amgen
TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb
LAB150 was created in 2017 with Evotec as the first North American BRIDGEs program to accelerate the development of novel therapeutics from our Members. Today’s announcement not only provides pre-seed capital of US$14M to these emerging drug development projects but also significant expertise and mentorship to our local scientists and innovators from ...
Read more
Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor.
Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ...
Read more
LAB150 adds project with focus on mental health
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) --
It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many antidepressant drugs on the market, most of these drugs need weeks to take effect, if at all. This exciting new project hopes to develop a novel rapid-acting antidepressant that has the potential to provide patient relief much faster than conventional treatments.
The project builds on years of research led by Dr. ...
Read more
LAB150 adds two projects: Cystic Fibrosis and Respiratory Syncytial Virus
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. LAB150 is a partnership between MaRS Innovation and Evotec AG with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms ...
Read more
Fibrocor Therapeutics enters deal with Galapagos NV
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs.
In 2017 MaRS Innovation founded, and subsequently seed-funded, Fibrocor. The company is based on research from two of MaRS Innovation’s Member institutions, St. Michael’s Hospital and Sinai Health Systems – specifically, from the labs of Drs. Richard ...
Read more
FIRST FUNDED PROJECT UNDER LAB150 BRIDGE ANNOUNCED!
Hamburg, Germany, and Toronto, Canada, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership.
After signing a collaboration agreement in September 2017, the first project within this academic BRIDGE has now been identified. The project aims to develop kallikrein-targeting compounds as novel topical drugs for the rare but severe inflammatory skin disease ‘Netherton Syndrome’ as well as ...
Read more
LAB150 – A new paradigm in drug discovery
Click on link to read an article by Drs. Rafi Hofstein and Werner Lanthaler published in December 2017 in the online publication Global University Venturing: http://bit.ly/2Ba9vH2
Read more
LAB150 – Strategic Partnership with Evotec AG
Toronto, Sept. 14, 2017 (GLOBE NEWSWIRE) -- MaRS Innovation (“MI”) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the launch of “LAB150”. This transformational Toronto-based partnership will give Canada access to the world-class infrastructure and drug discovery expertise of Evotec, and pair it with cutting-edge drug discovery projects emerging from the 15 Member institutions of MaRS Innovation.
A crucial lack of the funding, specialized infrastructure and drug development expertise necessary to translate disease-related biological pathways into focused drug ...
Read more